Telix Pharmaceuticals Limited
- TLX
- NASDAQ
- Biotechnology
- Radiopharmaceuticals
- Precision Medicine
- Cancer Diagnostics/Therapy
$10.74
Today +0.47%Quote Oct 19, 2026, 08:00 PM UTC
−14.55%over the last month
Max drawdown −16.2%From 1-month high −15.1%3 months +1.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Telix Pharmaceuticals
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Where the money comes from
Q2 2019 revenue $15.7M
- Digital Product Sales$11.7M74.6%
- Digital Product Lease And Maintenance$4.0M25.4%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
1,152
Founded
2015
Market value
$3.65B
Quote Oct 19
Analyst target
$18.00
+67.6% from here
Floor
$10.58
1.5% below price
Resistance
$10.85
1.0% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about TLXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free